Khalid Eljaaly, PharmD, an alumnus of the Clinical Research in Human Therapeutics program and now an honorary research fellow for the HOPE Center, received high-profile recognition for his recent work.
Dr. Eljaaly co-authored a journal article with David Nix, PharmD, professor, and Samah Alshehri, PharmD, also an alumnus of the Clinical Research in Human Therapeutics program and honorary research fellow for the Hope Center, titled Impact of Requiring Re-Authorization of Restricted Antibiotics on Day 3 of Therapy. The article was published in the JOURNAL OF ANTIMICROBIAL Chemotherapy, and was named one of 2017’s Significant Publications on Infectious Disease in the Journal of Pharmacy Practice. The American College of Clinical Pharmacy also linked to the article on Facebook.
The study compared two antibiotic stewardship programs (ASP) for restricted antibiotics - one that required initial authorization alone with one requiring subsequent re-authorization on day 3 of therapy. The researchers found the second ASP requiring re-authorization of restricted antibiotics on day 3 of therapy was associated with reduction in overall consumption of restricted antibiotics and length of hospital stay without adversely affecting hospital mortality.
Dr. Eljaaly and Dr. Alshehri additionally co-authored Contraindicated Drug–Drug Interactions Associated with Oral Antimicrobial Agents Prescribed in the Ambulatory Care Setting in the United States, with SANDIPAN BHATTACHARJEE, PhD, assistant professor and member of the HOPE Center. This study was published in the official journal of European Society of Clinical Microbiology and Infectious Diseases, which is ranked 7th in the field of infectious disease based on the Thompson Reuters' journal citation report (2017).
In this study, adult (age ≥18 years) ambulatory care visits involving prescriptions for oral antibacterial or antifungal agents were evaluated for potential drug–drug interaction (DDI) contraindications drug–drug interaction (DDI) contraindications. The study found that ~1.25 million visits over 7 years in U.S included a prescription of contraindicated DDIs between oral antibacterial/antifungal agents and other drugs. The most common ones were clarithromycin/erythromycin with simvastatin/lovastatin, followed by flouroquinolones with antiarrhythmic agents.